GlassScriptPhysician profile
Deep Atul Shah
NPI 1295266450
$8,442.44
in general payments reported to CMS, 2019-2025
26 companies · $2,405 in 2025
The $2,405 reported for 2025 was more than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
See the full distribution for Advanced Heart Failure and Transplant Cardiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $230 · 2020: $123 · 2021: $323 · 2022: $211 · 2023: $3,381 · 2024: $1,768 · 2025: $2,405.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,885 · Travel and Lodging: $1,492 · Education: $178.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,884.89 |
| Travel and Lodging | $1,491.86 |
| Education | $178.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,356.33 | 2023-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit, Diamondback Coronary |
| Astrazeneca Pharmaceuticals LP | $1,144.29 | 2020-2025 | Farxiga, Lokelma, Wainua |
| Abiomed | $764.26 | 2023-2025 | Impella |
| Scpharmaceuticals INC. | $426.83 | 2024-2025 | |
| Bridgebio Pharma, INC. | $420.36 | 2025 | Attruby |
| E.R. Squibb & Sons, L.L.C. | $364.59 | 2022-2025 | Camzyos, Eliquis |
| Boston Scientific Corporation | $228.94 | 2019-2023 | |
| United Therapeutics Corporation | $197.81 | 2025 | Tyvaso, Remodulin |
| Merck Sharp & Dohme LLC | $169.31 | 2024-2025 | Verquvo, Winrevair |
| Cardiac Dimensions, INC. | $142.67 | 2024 | |
| Medtronic, INC. | $130.60 | 2025 | Symplicity G3 |
| Novartis Pharmaceuticals Corporation | $129.63 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $121.83 | 2025 | Uptravi, Opsumit |
| Pfizer INC. | $118.79 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $118.38 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $115.95 | 2019 | |
| Daxor Corporation | $110.10 | 2024 | Bva-100 |
| Alnylam Pharmaceuticals INC. | $90.05 | 2025 | Amvuttra |
| Cvrx, INC. | $72.05 | 2024-2025 | Barostim Neo System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $66.16 | 2023-2025 | Lifevest |
| Amgen INC. | $52.69 | 2024-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $39.74 | 2023 | Xarelto |
| Kestra Medical Technology Services, INC. | $21.43 | 2025 | Assure Wcd |
| Kiniksa Pharmaceuticals International, Plc | $20.72 | 2024 | Arcalyst |
| Esperion Therapeutics, INC. | $13.97 | 2025 | Nexletol |
| Impulse Dynamics (USA) INC. | $4.96 | 2025 | Optimizer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deep Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.